Approximately 25% of familial amyotrophic lateral sclerosis (fALS) cases are due to mutations in superoxide dismutase 1 (SOD1). Mutant SOD1-mediated ALS is caused by a gain of toxic function and the SOD1 level in non-neuronal neighbors, including astrocytes, determines the progression of ALS. Therefore, we hypothesized that small molecules that reduce SOD1 protein levels in astrocytes might slow the progression of mutant SOD1-mediated ALS. We developed and optimized a cell-based, high-throughput assay to identify low molecular weight compounds that decrease SOD1 expression transcriptionally in human astrocyte-derived cells. Screening of a chemical library of 9600 compounds with the assay identified hit compounds that downregulate SOD1 expression in a dose-dependent manner. Western blot analysis showed that one hit compound significantly decreased the level of endogenous SOD1 protein in H4 cells. The hit compound inhibited phosphorylation of NF-E2 DNA binding protein (Nrf2), which is a transcription factor that upregulates the SOD1 transcription. Further analysis revealed that one existing drug also downregulated the SOD1 transcription in a cell-based assay as well as in the spinal cords of the ALS model mice when administered perorally. Our assay provides a powerful strategy for discovering novel drugs for treating familial SOD1-mediated ALS. Thimerosal, an organomercury compound, has been widely used as preservative in pediatric vaccines. Although fetal organomercury poisoning (fetal Minamata disease) is known to exhibit systemic effects on fetus, little is known regarding the mechanism of action of thimerosal during the embryonic period. In the present study, we examined whether embryonic exposure to thimerosal affects early development of serotonergic neuron. Thimerosal (1 mg Hg/kg in saline) was administrated by intramuscular injection into glutei maximi to embryonic day 9 (E9) pregnant rats (E9, susceptible time window for serotonergic development. Day of insemination = E1), and then E15 fetus were dissected out. Embryonic hindbrains were cut along the dorsal midline and mounted flatly (whole-mount preparation), and were fixed with 4% paraformaldehyde. Development of serotonergic neurons was examined immunohistochemically using anti-serotonin antibody. A dramatic increase in the number of serotoninergic neurons localized to the lateral portion of caudal raphe was observed in thimerosal group (n = 7) compared to control (n = 9) by 190% (Student's t-test, p < 0.01). Basic structure of the raphe between the thimerosal and control groups was not generally affected. These results suggest that embryonic exposure to thimerosal affects early serotonergic development. The neuroprotective effects of fructose-1,6-diphosphate (FDP), an intermediate metabolite of glycolysis and a free radical scavenger, on energy metabolism of rat brain slices exposed to ischemia-reperfusion insult were investigated by phosphorous nuclear magnetic resonance ( 31 P-NMR) spectroscopy. Brain slices (400 m-thick) were incubated in standard artificial cerebrospinal fluid (ACSF) with 1 mM FDP (FDP+) or ACSF only (FDP−) at 27.5
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• C. Brain slices were exposed to ischemia by halting the perfusion for 1 h. Levels of high-energy phosphates, phosphocreatine (PCr) and ␥-ATP, relative to pre-ischemic levels were measured by 31 P-NMR. Recovery level of phosphocreatine 1 h after ischemia was significantly higher when superfused with FDP+ than when superfused with FDP− (54% and 68%, respectively; p < 0.01). In FDP+, FDP signal decreased to 39% of pre-ischemic level during the ischemic period and recovered gradually to 83% by 1 h after reperfusion, suggesting utilization of exogenous FDP as energy substrate. FDP did not show neuroprotective effects in neuron-rich slices pretreated with 100 M fluorocitrate, a selective glial poison. No difference was observed in the recovery levels of ␥-ATP. Capacity of FDP to scavenge reactive oxygen species (hydroxyl radical) was measured by electron spin resonance spectrometry with the spin trapping method using CYPMPO. Although FDP is a potent radical scavenger with EC 50 of 21.6 mM, virtually no radical scavenging capacity was observed under the present experimental condition at 1 mM. It might be suggested that (1) intake of exogenous FDP as a metabolic substrate in glycolysis would be the potential mechanism of neuroprotective effects of FDP including glial production of lactate by aerobic glycolysis (astrocyte-neuron lactate shuttle), and (2) Objective: In many advanced countries with rapidly aging populations, healthcare for individuals suffering from dementia or depression is an important issue. To maximize quality of life (QOL), effective methods that can improve the symptoms of dementia and depression are necessary. Cosmetic therapy has recently received attention as a potentially effective method. Qualitative observations have shown that cosmetic therapy enhances expressive and communicative abilities in elderly individuals. However, quantitative evaluation of cosmetic therapy has been inadequate. We therefore evaluated the effects of cosmetic therapy on brain activity using electroencephalography (EEG). Methods: Subjects comprised 43 elderly women (mean age, 82.8 ± 6.5 years) living in elderly care facilities. We measured EEG during rest before and after a cosmetic therapy program comprising skin care and makeup lessons. For EEG analysis, we used the diagnosis method of neuronal dysfunction and neuronal activity topography, as these are recently developed methods. Both techniques analyze neuron dysfunction based on the unstable EEG characteristics of individuals with dementia and can detect abnormal patterns on EEG. Results: After cosmetic therapy, electrical distributions on the scalp changed to a more normal pattern, and the area showing abnormal fluctuations became smaller. These findings suggest that after cosmetic therapy, electrical distributions in subjects became closer to those in neurologically healthy individuals, and also suggest that cosmetic therapy can stabilize unstable neuronal activity. Conclusions: These results show that cosmetic therapy has a positive effect on brain activity in the elderly. We hope that these findings will encourage more people to use cosmetic therapy to improve QOL. doi:10.1016 QOL. doi:10. /j.neures.2011 
